Literature DB >> 18021278

Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b).

Sjoerd Klaver1, Steven Joniau, Raphael Suy, Raymond Oyen, Hein Van Poppel.   

Abstract

OBJECTIVE: To review our institutional experience of surgery for renal cell carcinoma (RCC) with subdiaphragmatic macroscopic venous invasion (T3b) and to assess variables associated with cancer-specific survival (CSS), as the stratification of RCC with venous involvement (T3b and T3c) is subject to debate. PATIENTS AND METHODS: We retrospectively reviewed the hospital records of patients who underwent a radical nephrectomy with resection of subdiaphragmatic tumour thrombus (T T) between October 1990 and May 2006. The log-rank and Cox uni- and multivariate regression analysis were used to evaluate predictive factors for CSS.
RESULTS: In all, 101 cases were identified. In the N0M0 group, univariate Cox regression analysis confirmed that ipsilateral adrenal gland invasion, Mayo Clinic level of T T, histological subtype and fat invasion were significantly associated with worse CSS. In multivariate Cox regression analysis, only Mayo Clinic level of T T was an independent predictor for CSS. In the subgroup with renal vein involvement only, the median CSS was not reached. In the subgroups with level I, II and III T T involvement, the median CSS was 69, 26 and 21 months, respectively. In the N+ and/or M+ group, only tumour size and type were independent predictors of CSS, while the level of T T was not. Radical nephrectomy yielded poor results with a median CSS of 13 months.
CONCLUSION: The Mayo Clinic level of T T is an independent prognostic predictor for CSS in non-metastatic T3b RCC. We strongly support the need for re-classification of the currently applied 2002 Tumour-Node-Metastasis staging system, which in its present form does not discriminate between levels of subdiaphragmatic venous invasion.

Entities:  

Mesh:

Year:  2007        PMID: 18021278     DOI: 10.1111/j.1464-410X.2007.07257.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

Review 1.  Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Authors:  Juan I Martínez-Salamanca; Estefania Linares; Javier González; Roberto Bertini; Joaquín A Carballido; Thomas Chromecki; Gaetano Ciancio; Sia Daneshmand; Christopher P Evans; Paolo Gontero; Axel Haferkamp; Markus Hohenfellner; William C Huang; Theresa M Koppie; Viraj A Master; Rayan Matloob; James M McKiernan; Carrie M Mlynarczyk; Francesco Montorsi; Hao G Nguyen; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Krishna Ramaswamy; Oscar Rodriguez Faba; Paul Russo; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

2.  Challenging surgery for retroperitoneal tumors and liver transplant surgeons.

Authors:  Murat Akyol
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

3.  Radical nephrectomy with resection of vena cava thrombus using extracorporeal circulation and deep hypothermic circulatory arrest.

Authors:  Gregory J Nason; Khaled Ajib; Guan Hee Tan; Dixon T S Woon; George T Christakis; Robert K Nam
Journal:  Can Urol Assoc J       Date:  2021-04       Impact factor: 1.862

4.  Determinants of outcomes after resection of renal cell carcinoma with venous involvement.

Authors:  Abhinav Sidana; Jatinder Goyal; Piyush Aggarwal; Payal Verma; Ronald Rodriguez
Journal:  Int Urol Nephrol       Date:  2012-10-20       Impact factor: 2.370

5.  Radical nephrectomy and intracaval thrombectomy for advanced renal cancer with extensive inferior vena cava involvement utilising cardiopulmonary bypass and hypothermic circulatory arrest: Is it worthwhile?

Authors:  Hosam Serag; Jonathan M Featherstone; David F Griffiths; Dheeraj Mehta; John Dunne; Owen Hughes; Philip N Matthews
Journal:  Arab J Urol       Date:  2018-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.